Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Antiphospholipid syndrome

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Testicular cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Invasive candidiasis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Bipolar disorders

    Research output: Contribution to journalReviewResearchpeer-review

  4. Narcolepsy

    Research output: Contribution to journalReviewResearchpeer-review

  5. Diabetic retinopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalReviewResearchpeer-review

  3. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  • Karen Schreiber
  • Savino Sciascia
  • Philip G de Groot
  • Katrien Devreese
  • Soren Jacobsen
  • Guillermo Ruiz-Irastorza
  • Jane E Salmon
  • Yehuda Shoenfeld
  • Ora Shovman
  • Beverley J Hunt
View graph of relations

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein 1 antibodies. APS can present with a variety of clinical phenotypes, including thrombosis in the veins, arteries and microvasculature as well as obstetrical complications. The pathophysiological hallmark is thrombosis, but other factors such as complement activation might be important. Prevention of thrombotic manifestations associated with APS includes lifestyle changes and, in individuals at high risk, low-dose aspirin. Prevention and treatment of thrombotic events are dependent mainly on the use of vitamin K antagonists. Immunosuppression and anticomplement therapy have been used anecdotally but have not been adequately tested. Pregnancy morbidity includes unexplained recurrent early miscarriage, fetal death and late obstetrical manifestation such as pre-eclampsia, premature birth or fetal growth restriction associated with placental insufficiency. Current treatment to prevent obstetrical morbidity is based on low-dose aspirin and/or low-molecular-weight heparin and has improved pregnancy outcomes to achieve successful live birth in >70% of pregnancies. Although hydroxychloroquine and pravastatin might further improve pregnancy outcomes, prospective clinical trials are required to confirm these findings.

Original languageEnglish
JournalNature reviews. Disease primers
Volume4
Issue number17103
Pages (from-to)17103
ISSN2056-676X
DOIs
Publication statusPublished - 11 Jan 2018

ID: 56674510